Provention Bio Initiates P-IIa (PREVAIL-2) Study of PRV-3279 for the Treatment of Systemic Lupus Erythematosus
Shots:
- The company initiates the P-IIa (PREVAIL-2) POC study to evaluate the efficacy & safety of PRV-3279 (q4w for 5mos.) vs PBO in ~100 patients with SLE across ~28 sites in the US & Hong Kong. The results are expected in 2024
- The 1EPs is to evaluate the ability of PRV-3279 to reduce SLE flare. The therapy was well-tolerated in a prior SAD in P-I study & MAD in P-Ib (PREVAIL-1) study, reduction in IgM production @8wks.
- The company collaborated with Hangzhou Zhongmei Huadong to develop & commercialize PRV-3279 in Greater China. PRV-3279 is a humanized bispecific DART molecule targeting CD32B & CD79B & has the potential to intercept the pathophysiology of SLE & B cell-mediated autoimmune diseases
Ref: PR Newswire | Image: Provention Bio
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com